TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03250689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled COPD maintenance medication
Description: Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled COPD maintenance medication
Description: Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist \[LAMA\], long-acting beta-agonist \[LABA\]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
Study: NCT04078295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: E7389-LF Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7389-LF
Description: E7389-LF Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Intravenous infusion.
Study: NCT01977677

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03729401

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Dual Antiplatelet Therapy (DAPT) - Aspirin 81 mg + Ticagrelor 60mg twice daily
Description: DAPT with aspirin and ticagrelor
Study: NCT02318849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web intervention
Description: interactive website using social media and gamification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web intervention
Description: interactive website using social media and gamification

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web intervention
Description: interactive website using social media and gamification
Study: NCT03184311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIT)
Description: Supervised 12-week HIT 3 times per week on a bicycle ergometer.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moderate-intensity contiuous training (MCT)
Description: Supervised 12-week MCT 3 times per week on a bicycle ergometer.
Study: NCT03492229

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: 1 mA of tDCS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: 1 mA of tDCS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AMT
Description: Ankle motor training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AMT
Description: Ankle motor training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: High intensity treadmill training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treadmill training
Description: High intensity treadmill training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: High intensity treadmill training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill training
Description: High intensity treadmill training
Study: NCT03535857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS
Description: Use of PTNS on the ankle for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTNS
Description: Use of PTNS on the ankle for 30 minutes
Study: NCT01136018

Intervention type: PROCEDURE
Intervention: insertion needle via intentionally lateral direction.
Description: evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
Study: NCT03335800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple Heart Study App
Description: The Apple Heart Study app is a mobile medical app that analyzes pulse rate data. The app identifies episodes of irregular heart rhythms consistent with atrial fibrillation and other arrhythmias.
Study: NCT05549583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
Description: The subjects randomly received single oral dose of Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
Study: NCT02193750

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Moderate Oligosaccharide Group
Description: 1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Oligosaccharide Group
Description: 1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
Study: NCT01566604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVA237
Description: Delivered via a single dose dry powder inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Delivered via a single dose dry powder inhaler
Study: NCT03049878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol Codeine
Description: preoperative administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: preoperative administration
Study: NCT02903342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leaflet
Description: A leaflet designed from data obtained from previous qualitative and quantitative studies.
Study: NCT01204203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
Study: NCT01122069

Intervention type: OTHER
Intervention: Perflutren Lipid Microsphere ultrasound contrast
Description: Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
Study: NCT01973218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal B Recombinant vaccine rMenB+OMV NZ
Description: Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ACWY-CRM conjugate vaccine
Description: Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
Study: NCT04322032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D759 Tab. 1 Tab. and D308 Tab. 1 Tab.(Total 2 Tab.), Single oral administration under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug
Description: CKD-389 Tab. 1 Tab.(Total 1 Tab.), Single oral administration under fasting condition.
Study: NCT00570375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
Study: NCT02770911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without Dog Ear group
Description: a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with Dog Ear group
Description: a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
Study: NCT02570347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Description: Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Co-amoxiclav
Description: Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Description: Injection Tetanus toxoid 0.5 ml intramuscularly Stat

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid
Description: Injection Tetanus toxoid 0.5 ml intramuscularly Stat
Study: NCT00529711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic lactate
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's lactate
Description: Solution given parenterally as follows:~Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Study: NCT03729401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Monotherapy: Ticagrelor 60 mg twice daily
Description: Ticagrelor monotherapy
Study: NCT03744442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dignity Therapy (DT) module
Description: psychotherapeutic intervention asking patients about their most important achievements, roles and other important aspects of life; two structured sessions of 60 minutes conducted by a trained therapist
Study: NCT03729401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Personalized Therapy Arm: Aspirin 81 mg or Ticagrelor 60mg twice daily or Clopidogrel 75 mg once daily
Description: Personalized therapy based on risk score and genotyping
Study: NCT03744442

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CALM Therapy module
Description: supportive-expressive psychotherapy aiming to help (1) manage the disease, symptom and treatment, and communicate with healthcare providers, to (2) adjust to changes in self-concept, personal relationships, and support needs, to (3) find a sense of meaning and purpose in life, and to (4) prepare for the future, sustain hope, and face the end of life; two structured sessions of 60 minutes conducted by a trained therapist

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based interventions module
Description: Mind-body techniques reducing existential and spiritual distress and dealing with common experiences related to life-limiting diseases, including loss of control, uncertainty about the future; two structured sessions of 60 minutes conducted by a trained therapist
Study: NCT03920085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Verio
Description: OneTouch Verio Blood Glucose Monitoring System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Select Plus
Description: OneTouch Select Plus Blood Glucose Monitoring System.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch Ultra
Description: OneTouch Ultra Blood Glucose Monitoring System.
Study: NCT00567567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study: NCT05237726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 mg q24 hours
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 30 mg q12 hours
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin 5000 U q8 hours
Description: Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.
Study: NCT03433677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered by CSII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered by CSII
Study: NCT00750295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBR759
Description: Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
Study: NCT03585010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Parenting for Anxious Childhood Emotions
Description: 12 sessions with parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Educational Support
Description: 12 sessions with parents

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy
Description: 12 sessions with child
Study: NCT00325689

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine or Risperidone + Aripiprazole
Description: Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quetiapine or Risperidone + placebo
Description: Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
Study: NCT00974818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Description: Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
Study: NCT00198770

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary substitution to assess level of caloric compensation
Description: Mushrooms substituted for meat in dishes
Study: NCT02735928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin
Description: After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (\< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 10.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 2.1 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
Study: NCT00142090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Hypertonic saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT03774810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate
Description: Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate
Description: Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate
Description: Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem tartrate
Description: Zolpidem Tartrate, 5mg for men older than 60 and women of all ages. 10 mg for men younger than 60.
Study: NCT00225745

Intervention type: PROCEDURE
Intervention: Blood draw
Description: One blood draw prior to first treatment

Intervention type: PROCEDURE
Intervention: Blood draw
Description: One blood draw prior to first treatment
Study: NCT02690272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychic processes
Description: Quantitative and qualitative aprroche of the psychic process
Study: NCT01747356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute stent treatment
Description: A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
Study: NCT00672568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975 - Highly purified capsaicin
Description: Solution, 0.5 mg, single dose, injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975 - Highly purified capsaicin
Description: Solution, 0.75 mg, single dose, injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4975 - Highly purified capsaicin
Description: Solution, 0.1 mg, Single dose, injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution, single dose, injection
Study: NCT01168921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Starting dose 75 mg by mouth (PO) daily for 28 day cycle
Study: NCT00908271

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
Study: NCT06047639

Intervention type: DEVICE
Intervention: Bone-anchored hearing implants
Description: surgically placed hearing device